



COAGULATION DEFECTS IN CERTAIN TYPES OF MALIGNANCY



Thesis

*Submitted in partial fulfilment
for the M. D. Degree in Biochemistry*



ASHRAF MAHMOUD MOURAD

*Assistant Lecturer of Biochemistry
Faculty of Medicine
El-Minia University*

**Biochemistry Department
Faculty of Medicine
Ain Shams University**

1991



ACKNOWLEDGEMENT

Thanks to Allah The Most Helpful

Words cannot express how much I should be grateful and thankful to both Prof. Dr. **SALAH EL-DIN ZAKI EID**, Professor of Biochemistry and Dean of the Faculty of Medicine, Ain Shams University and Prof. Dr. **STUART GORDON**, Associate Professor of Medicine, Medical School, Health Sciences Center, University of Colorado, U.S.A. They suggested the title of the thesis, directed the practical work, and continuously supervised the whole work.

To Prof. Dr. **HAMDY ABD ALLAH**, Professor of General Surgery, Faculty of Medicine, Ain Shams University, I should be very grateful for supplying me by the malignant cases at the beginning of my research work.

I do not know how words can appreciate the help of Dr. **ABD EL-MONEIM FOOLY GALAL**, Assistant Professor of Biochemistry, Faculty of Medicine, El-Minia University. I owe too much to his supervision, encouragement, and advice.

Also, I wish to express to Dr. **MAGDA NAGATY IBRAHIM**, Assistant Professor of Biochemistry, Faculty of Medicine, Ain Shams University, my deepest thanks and gratitude for her continuous supervision and advice throughout the whole work.

My deep thanks to Dr. **MAHMOUD ISMAEL HASSAN**, Assistant Professor of Biochemistry and Dr. **SALWA HADAD**, Assistant Professor of Pathology, Faculty of Medicine, Ain Shams University, for their continuous advice and encouragement.

It is an honour for me to express my appreciation to Dr. **RICHARD MARLAR**, Hematology Department, Veteran Administration Hospital, Denver, CO, for his great help in the work related to both thrombomodulin and protein S. Also, it was very kind from Dr. **STEVE CARSON**, Department of Pathology and Microbiology, University of Nebraska, Medical Center, Omaha, NE, U.S.A., to offer the antibody against tissue factor that was used in the factor X assay.

Lastly, I would like to express my deep and heartfelt gratitude for the Egyptian government for their financial support of my fellowship provided by El-Minia University and their continuous cooperation with my family. I am grateful to the United States of America for two years in spite of the hard economic position facing my country.

LIST OF FIGURES

Figure 1.	The pathway of blood coagulation.....	5
Figure 2.	Homologous domains in the structures of some of the proteins involved in hemostasis.....	9
Figure 3.	Comparison between serine and cysteine proteinases.....	34
Figure 4.	Thrombomodulin dilution curve.....	65
Figure 5.	Characterization of polyclonal goat anti-cancer procoagulant antibody.....	72
Figure 6.	RVV standard curve.....	73
Figure 7.	SDS-PAGE of cancer procoagulant at various stages of purification.....	74
Figure 8.	SDS-PAGE of cancer procoagulant purification steps.....	76
Figure 9.	Thrombomodulin standard curve.....	77
Figure 10.	Silver stained gel of purified thrombomodulin.....	78
Figure 11.	Effect of cancer procoagulant on thrombomodulin activity.....	79
Figure 12.	Protein S standard curve.....	81
Figure 13.	Effect of cancer procoagulant on protein S activity.....	82

Figure 14. SDS-PAGE of protein S at different time of incubation with cancer procoagulant.....	83
Figure 15. Western blotting of protein S at various time of incubation with cancer procoagulant.....	84
Figure 16. Non-reducing SDS-PAGE of human factor X activated by both cancer procoagulant and the protease from Russell's viper venom.....	86
Figure 17. SDS-PAGE of human factor X activated by cancer procoagulant after reduction with B-mercaptoethanol.....	87
Figure 18. Activation of purified factor X with a partially purified cancer procoagulant on a 10% SDS-PAGE.....	89
Figure 19. SDS-PAGE of the effect of a partially purified cancer procoagulant on human factor X after inhibition of the tissue factor activity in the sample with a purified inhibitory antibody against tissue factor.....	90

LIST OF TABLES

Table 1.	Properties of the genes, mRNA, and gene products of the components of the blood coagulation cascade.....	4
Table 2.	Cancer procoagulant amino acid composition.....	38
Table 3.	Comparison of six amino acids of cancer procoagulant with other factor X activators.....	38
Table 4.	Amnion-chorion procoagulant amino acid composition.....	40
Table 5.	Sources of cancer procoagulant.....	48
Table 6.	Identification of cancer procoagulant antigen in serum of patients with active malignant disease, phase I.....	51
Table 7.	Identification of cancer procoagulant antigen in serum of patients with active malignant disease, phase II.....	51
Table 8.	Comparison of the published amino terminal sequence of factor X _a and the sequence determined in our experiment.....	92

LIST OF ABBREVIATIONS

vWF	von Willibrant Factor
EGF	Epidermal Growth Factor
LACI	Lipid-Associated Coagulation Inhibitor
RVV	The proteinase from Russell's Viper Venom
Gla	-carboxy glutamic acid
PCA	Procoagulant Activity
PCMB	P-chloro-mercurial-benzoate-agarose
NBT	Nitroblue tetrazolium
BCIP	5-Bromo, 4-chloro, 3-indolyl phosphate
SDS	Sodium Dodecyl Sulfate
SDS-PAGE	Sodium Dodecyl Sulfate-Polyacrylamide Slab Gel Electrophoresis
PVDF	Polyvinylidene difluoride
Mr	Molecular rate of migration.

TABLE OF CONTENTS

INTRODUCTION	1
REVIEW OF LITERATURE	3
BLOOD COAGULATION	3
The intrinsic pathway	3
The extrinsic pathway	6
The common pathway	6
Function	7
Structure	8
Tissue factor	10
Factor VII	11
Factor X	12
Fibrinogen	15
PROTEIN C ANTICOAGULANT PATHWAY	16
Thrombomodulin	16
Protein C	18
Protein S	18
CANCER CELL PROCOAGULANT ACTIVITY	20
Fibrin deposition in cancer	20
Tissue factor activity in cancer	23
CANCER PROCOAGULANT	31
Discovery	31
Mechanism of action	32
Purification	37
Isolation from a human source	39
Identification in tissue samples	42
Identification in culture cells	42
Identification in melanoma	44
Identification in acute leukemia	45
Potential in cancer therapy	46
Potential tumor marker	47
AIM OF THE WORK	52
MATERIAL AND METHODS	54
RESULTS	71
DISCUSSION	92
CONCLUSION	96
SUMMARY	97
REFERENCES	98

INTRODUCTION

INTRODUCTION

Different effects on blood coagulation are known to be associated with malignancies in experimental animals, tissue culture cells, and human. Evidence has been accumulated to suggest that inhibition of blood coagulation is effective in decreasing the incidence of metastatic formation and can even cause suppression of the growth of the tumor. Malignant cells are known to produce various materials (procoagulants) that can affect blood coagulation at various sites of the cascade. Various types of these procoagulants have been described. In this review of the literature, I will describe the general mechanism of blood coagulation and the properties of some coagulation factors that are known to be affected in malignancy. I will also describe the properties of the proteins constituting a pathway that is important in the regulation of blood coagulation, the protein C anticoagulant pathway. Finally, I will discuss the different properties of cancer procoagulant.

This will explain the importance of studying the effect of cancer procoagulant on the blood coagulation human factor X and on the two cofactors of the protein C anticoagulant pathway, thrombomodulin and protein S.

Studying the effect of cancer procoagulant on its natural substrates could provide the information required to synthesize a specific substrate or inhibitor for cancer procoagulant that can be applied for the diagnosis and probably the treatment of malignancy.

REVIEW OF LITERATURE

BLOOD COAGULATION

Blood coagulation is a type of host defense system composed of a complex response of the vascular system, circulating platelets and monocytes, coagulation proteins, and the fibrinolytic system towards blood vessel injury. The activation of the proenzymes (designated by Roman numeral, e.g. XII) of blood coagulation to their active enzyme forms (designated by "a" after the Roman numeral, e.g. XII_a) proceeds through either the extrinsic or the intrinsic pathway (Davie and Ratnoff, 1964; and MacFarlane, 1964).

In these blood coagulation pathways many of the enzyme reactions take place within complexes that are associated with cell membranes; for example factor X activation takes place in factor VIII_a, IX_a, and X complex when VIII_a is associated with a cell membrane or a phospholipid bilayer. Phospholipid in *in vitro* experiments replaces the cell membrane *in vivo*.

The intrinsic pathway: The intrinsic pathway of blood coagulation was given the name "intrinsic" because all of required proteins are in the blood. In contrast, the extrinsic pathway requires a glycoprotein associated with the cell membrane of many tissues. The intrinsic pathway (figure 1) is activated in the presence of a

Table 1. Properties of the genes, mRNA and gene products of the components of the blood coagulation cascade (Furie and Furie, 1988).

Component	Molecular weight	Gene (Kb)	mRNA (Kb)	Plasma conc. (µg/ml)	Function
Prothrombin	72,000	21	2.1	100.0	Proteinase zymogen
Factor X	56,000	22	1.5	10.0	Proteinase zymogen
Factor IX	56,000	34	2.8	5.0	Proteinase zymogen
Factor VII	50,000	31	2.4	0.5	Proteinase zymogen
Factor VIII	330,000	185	9.0	0.1	Cofactor
Factor V	330,000		7.0	10.0	Cofactor
Factor XI	160,000	23		5.0	Proteinase zymogen
Factor XII	80,000	12	2.4	30.0	Proteinase zymogen
Fibrinogen	340,000			3000.0	Structural
Aα chain	66,000				
BB chain	52,000				
chain	46,000				
Protein C	62,000	11	1.8	4.0	Proteinase zymogen
Protein S	80,000		2.4	25.0	Cofactor
vWF	225,000x n ^a	175	8.5	10.0	Adhesion
Tissue factor	37,000		2.1	0.0	Cofactor/initiator

n^a = number of subunits , where the subunit Mr is 225,000.